Amount of acquired IPRD expense related to the fair value of common stock and warrant shares issued per agreement.

No definition available.

Name:	ecyt_AcquiredInProcessResearchAndDevelopmentExpenseRelatedToFairValueOfCommonStockAndWarrantsIssued
Namespace Prefix:	ecyt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of acquired IPRD expense related to acquisition costs consisting primarily of legal and professional fees.

+ References

No definition available.

+ Details

Name:	ecyt_AcquiredInProcessResearchAndDevelopmentExpenseRelatedToLegalAndProfessionalFeeAcquisitionCosts
Namespace Prefix:	ecyt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Amount of acquired IPRD expense related to the upfront payment made per agreement.

+ References

No definition available.

+ Details

Name:	ecyt_AcquiredInProcessResearchAndDevelopmentExpenseRelatedToUpfrontPayment
Namespace Prefix:	ecyt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

n/a

+ References

No definition available.

+ Details

Name:	ecyt_BXDevelopmentAndLicenseAgreementAbstract
Namespace Prefix:	ecyt_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of consideration issued for the license agreement excluding shares of common stock and warrants.

+ References

No definition available.

+ Details

Name:	ecyt_CashConsiderationForLicenseAgreement
Namespace Prefix:	ecyt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Represents the period of time after the first commercial sale in Japan for notice to exercise right of termination to be given.

+ References

No definition available.

+ Details

Name:	ecyt_CollaborativeArrangementRightOfTerminationNoticePeriodAfterFirstCommercialSaleInJapan
Namespace Prefix:	ecyt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the period of time after receiving regulatory approval in Japan that NMP may terminate the collaborative agreement if the Company fails to launch the product.

+ References

No definition available.

+ Details

Name:	ecyt_CollaborativeArrangementRightOfTerminationNoticePeriodAfterReceiptOfRegulatoryApprovalIfCompanyFailsToLaunchProduct
Namespace Prefix:	ecyt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the period of time prior to the first commercial sale in Japan for notice to be given to exercise right of termination of the agreement.

+ References

No definition available.

+ Details

Name:	ecyt_CollaborativeArrangementRightOfTerminationNoticePeriodPriorToFirstCommercialSaleInJapan
Namespace Prefix:	ecyt_
Data Type:	xbrli:durationItemType
Balance Type:	na
Period Type:	duration

- Definition

Future milestone payments that could be paid upon achievement of certain milestones per agreement.

+ References

No definition available.

+ Details

Name:	ecyt_FutureMilestonePayments
Namespace Prefix:	ecyt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

n/a

+ References

No definition available.

+ Details

Name:	ecyt_NMPLicenseAndCommercializationAgreementAbstract
Namespace Prefix:	ecyt_
Data Type:	xbrli:stringItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of indications that trigger payment of milestones under the agreement.

+ References

No definition available.

+ Details

Name:	ecyt_NumberOfIndicationsTriggeringMilestonePaymentsUnderAgreement
Namespace Prefix:	ecyt_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of patients to be included in a joint phase 2 multi-center TheraP trial.

+ References

No definition available.

+ Details

Name:	ecyt_NumberOfPatientsInJointPhase2MultiCenterTrial
Namespace Prefix:	ecyt_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

The number of warrants to purchase common stock issued per the license agreement.

+ References

No definition available.

+ Details

Name:	ecyt_NumberOfWarrantsIssuedPerAgreement
Namespace Prefix:	ecyt_
Data Type:	xbrli:integerItemType
Balance Type:	na
Period Type:	duration

- Definition

Represents the potential payment that may be received upon achievement of specified milestones per agreement.

+ References

No definition available.

+ Details

Name:	ecyt_PotentialPaymentForAchievementOfSpecifiedMilestones
Namespace Prefix:	ecyt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

The amount of acquired in-process research and development expense recorded in connection with license agreement.

+ References

No definition available.

+ Details

Name:	ecyt_ResearchAndDevelopmentInProcessAcquiredExpense
Namespace Prefix:	ecyt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	duration

- Definition

Number of shares of stock issued during the period pursuant to asset acquisition.

+ References

No definition available.

+ Details

Name:	ecyt_StockIssuedDuringPeriodSharesAssetAcquisition
Namespace Prefix:	ecyt_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	duration

- Definition

Amount of upfront fees paid per agreement.

+ References

No definition available.

+ Details

Name:	ecyt_UpfrontFeesPaid
Namespace Prefix:	ecyt_
Data Type:	xbrli:monetaryItemType
Balance Type:	debit
Period Type:	instant

- Definition

Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

+ Details

Name:	us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights
Namespace Prefix:	us-gaap_
Data Type:	xbrli:sharesItemType
Balance Type:	na
Period Type:	instant

- Definition

Amount of deferred revenue as of balance sheet date. Deferred revenue represents collections of cash or other assets related to a revenue producing activity for which revenue has not yet been recognized. Generally, an entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenue
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	instant

- Definition

Amount of deferred revenue recognized for transactions arising during the current reporting period. Deferred revenue is a liability as of the balance sheet date related to a revenue producing activity for which revenue has not yet been recognized. Generally, an Entity records deferred revenue when it receives consideration from a customer before achieving certain criteria that must be met for revenue to be recognized in conformity with GAAP.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB TOPIC 13.A.4(a).Q1)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

Reference 2: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SAB Topic 13.A.3)
-URI http://asc.fasb.org/extlink&oid=65893310&loc=d3e214044-122780

+ Details

Name:	us-gaap_DeferredRevenueAdditions
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Definition

The amount of consideration recognized during the period for the milestone or milestones.

+ References

Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 605
-SubTopic 28
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=68058744&loc=SL6892177-166501

+ Details

Name:	us-gaap_RevenueRecognitionMilestoneMethodRevenueRecognized
Namespace Prefix:	us-gaap_
Data Type:	xbrli:monetaryItemType
Balance Type:	credit
Period Type:	duration

- Details

Name:	us-gaap_CounterpartyNameAxis=ecyt_AbXMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ecyt_LicenseAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=ecyt_AchievementOfRegulatoryMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=ecyt_AchievementOfSalesMilestonesMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_StatementScenarioAxis=us-gaap_ScenarioForecastMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_CounterpartyNameAxis=ecyt_NmpMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_TypeOfArrangementAxis=ecyt_LicenseAndCommercializationAgreementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_DeferredRevenueArrangementTypeAxis=us-gaap_UpFrontPaymentArrangementMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

- Details

Name:	us-gaap_RangeAxis=us-gaap_MaximumMember
Namespace Prefix:
Data Type:	na
Balance Type:
Period Type:

Collaborations (Details)		1 Months Ended		3 Months Ended	9 Months Ended	50 Months Ended
Collaborations (Details)	Sep. 29, 2017 USD ($) item shares	Oct. 31, 2017 item	Aug. 31, 2013 USD ($) item	Sep. 30, 2017 USD ($)	Sep. 30, 2017 USD ($)	Sep. 30, 2017 USD ($)
ABX Development and License Agreement
Research And Development In Process Acquired Expense				$ 16,493,132	$ 16,493,132
ABX \| License Agreement
ABX Development and License Agreement
Upfront cash payment	$ 11,900,000
Total consideration excluding common stock shares and warrants	$ 12,000,000
Stock Issued During Period Shares Asset Acquisition \| shares	2,000,000
Number of warrants issued per agreement \| item	2
Aggregate number of common stock shares that may be purchased by exercise of warrants \| shares	4,000,000
Research And Development In Process Acquired Expense					16,500,000
Portion of acquired IPRD expense related to the upfront fee paid					12,000,000
Portion of acquired IPRD expense related to the fair value of the common stock and warrants issued					3,800,000
Portion of acquired IPRD expense related to legal and professional fees					700,000
ABX \| Achievement Of Regulatory Milestones \| License Agreement
ABX Development and License Agreement
Potential milestone payments to be paid				25,000,000	25,000,000	$ 25,000,000
ABX \| Achievement Of Sales Milestones \| License Agreement
ABX Development and License Agreement
Potential milestone payments to be paid				135,000,000	135,000,000	135,000,000
ABX \| Forecast
ABX Development and License Agreement
Number of mCRPC patients included in phase 2 multi-center trial \| item		200
NMP \| License And Commercialization Agreement
NMP License and Commercialization Agreement
Deferred Revenue				$ 800,000	$ 800,000	800,000
Milestone revenue recognized						$ 0
Period of time for termination notice to be given prior to the first commercial sale in Japan			90 days
Period of time for termination notice to be given after the first commercial sale in Japan			6 months
Period of time for termination notice to be given after Company receives regulatory approval in Japan but fails to launch the product			6 months
NMP \| Up-front Payment Arrangement \| License And Commercialization Agreement
NMP License and Commercialization Agreement
Upfront payment received			$ 1,000,000
NMP \| Achievement Of Regulatory Milestones \| License And Commercialization Agreement
NMP License and Commercialization Agreement
Number of cancer indications requiring achievement of regulatory goals \| item			5
NMP \| Achievement Of Regulatory Milestones \| Maximum \| License And Commercialization Agreement
NMP License and Commercialization Agreement
Potential milestone payment			$ 4,500,000